Expression Profiling Identified TRPM7 and HER2 as Potential Targets for the Combined Treatment of Cancer Cells
TRPM7 is a divalent cation-permeable channel that is highly active in cancer cells. The pharmacological inhibitors of TRPM7 have been shown to suppress the proliferation of tumor cells, highlighting TRPM7 as a new anticancer drug target. However, the potential benefit of combining TRPM7 inhibitors w...
Saved in:
| Main Authors: | Miyuki Egawa, Eva Schmücker, Christian Grimm, Thomas Gudermann, Vladimir Chubanov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/13/21/1801 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer
by: Shufen Mo, et al.
Published: (2025-01-01) -
Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database
by: Sarah Waliany, et al.
Published: (2024-12-01) -
Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer
by: Jing-Jing Liu, et al.
Published: (2024-11-01) -
Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer
by: Wang H, et al.
Published: (2024-11-01) -
Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01)